Table 3.
Efficacy end‐points related to patients with active psoriatic arthritis
| Efficacy outcomes | Week 16 | Through week 52 | |||||
|---|---|---|---|---|---|---|---|
| Placebo (n = 4) | Guselkumab 50 mg (n = 3) | Guselkumab 100 mg (n = 3) | Placebo → guselkumab 50 mg (n = 1) | Placebo → guselkumab 100 mg (n = 1) | Guselkumab 50 mg (n = 3) | Guselkumab 100 mg (n = 3) | |
| ACR response, n (%) | |||||||
| ACR‐20 | 0 | 3 (100.0) | 3 (100.0) | 1 (100.0) | 1 (100.0) | 3 (100.0) | 1 (33.3) |
| ACR‐50 | 0 | 2 (66.7) | 3 (100.0) | 1 (100.0) | 1 (100.0) | 2 (66.7) | 1 (33.3) |
| ACR‐70 | 0 | 1 (33.3) | 3 (100.0) | 1 (100.0) | 0 | 2 (66.7) | 1 (33.3) |
| Change in tender joint count, mean (SD) | 1.8 (2.36) | −8.3 (10.12) | −9.3 (4.93) | −3.0 (–) | 4.0 (–) | −10.3 (9.45) | −10.7 (7.23) |
| Change in swollen joint count, mean (SD) | 0.5 (2.52) | −3.3 (2.52) | −9.0 (3.00) | −10.0 (–) | −3.0 (–) | −4.3 (1.53) | −3.0 (8.19) |
| Change in patient's assessment of pain (VAS), mean (SD) | 0.80 (1.47) | −5.07 (2.20) | −5.43 (0.64) | −5.60 (–) | −4.80 (–) | −4.60 (4.00) | −3.63 (3.07) |
| Change in patient's global assessment of disease activity (VAS), mean (SD) | 0.55 (1.75) | −5.60 (1.71) | −6.00 (1.11) | −6.60 (–) | −4.80 (–) | −5.07 (3.33) | −3.63 (2.45) |
| Change in physician's global assessment of disease activity (VAS), mean (SD) | 1.63 (3.25) | −5.70 (3.12) | −3.27 (1.08) | −10.00 (–) | −2.10 (–) | −6.17 (1.52) | −2.20 (2.42) |
| HAQ‐DI responders, n (%) | 0 | 2 (66.7) | 2 (66.7) | 1 (100.0) | 0 | 2 (66.7) | 1 (33.3) |
ACR, American College of Rheumatology; HAQ‐DI, Health Assessment Questionnaire – Disability Index; PsA, psoriatic arthritis; SD, standard deviation; VAS, visual analog scale.